| 产品详情 |
| Edit |   |
|---|
| Product Name | LBH-589 (Panobinostat, NVP-LBH589) |
|---|
| Description | Purity ≥99%. Panobinostat, a histone deacetylase inhibitor, is being tested in humans against cutaneous T cell lymphoma, prostate cancer, myelodysplastic syndromes, breast cancer, chronic myelogenous leukemia, and other types of malignant disease. Panobinostat inhibited histone deacetylase and induced acetylation of histone H3 and alpha-tubulin protein in human umbilical vein endothelial cells (HUVEC), which resulted in induction of G(2)-M cell cycle arrest and inhibition of HUVEC proliferation and viability. Panobinostat at noncytotoxic concentrations inhibited endothelial tube formation, Matrigel invasion, AKT activity, extracellular signal-regulated kinase 1/2 phosphorylation and chemokine receptor CXCR4 expression. It aslo reduced angiogenesis and PC-3 tumor growth in mice. Synonyms: (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide; LBH 589; LBH-589 CAS No: 404950-80-7 |
|---|
| Size | 5mg, 10mg, 25mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide; LBH 589; LBH-589 |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | L1535 |
|---|
| Price | |
|---|
| Order / More Info | LBH-589 (Panobinostat, NVP-LBH589) from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|